Ventyx Biosciences(US:VTYX) 美股IPO·2026-01-06 23:16Core Viewpoint - Eli Lilly is in late-stage negotiations to acquire biotech company Ventyx Biosciences for over $1 billion, leading to a 57% surge in Ventyx's stock price after market close [1]. Company Overview - Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for autoimmune diseases, inflammatory diseases, and neurodegenerative diseases [2]. - The company's core pipeline includes NLRP3 inhibitors, with key products VTX2735 and VTX3232, both in Phase 2 development [2][3]. Product Pipeline and Clinical Development - VTX2735 is a peripheral NLRP3 inhibitor targeting recurrent pericarditis, with Phase 2 data expected in the second half of 2025 [3][4]. - VTX3232 is a CNS-penetrant NLRP3 inhibitor aimed at treating Parkinson's disease and cardiometabolic diseases, with positive Phase 2a data anticipated in June 2025 and additional data expected in the second half of 2025 [3][4]. - The inflammatory bowel disease portfolio includes Tamuzimod, a Phase 3-ready S1P1R modulator for ulcerative colitis, and VTX958, a TYK2 inhibitor for Crohn's disease, which has completed Phase 2 trials [3][4]. Financial Position - As of March 31, 2025, Ventyx reported cash, cash equivalents, and marketable securities totaling $228.8 million, expected to fund operations into at least the second half of 2026 [3].